Daily Stock Analysis, AAAP, Advanced Accelerator Applications SA, priceseries

Advanced Accelerator Applications SA. Daily Stock Analysis
Stock Information
Open
81.10
Close
81.20
High
81.25
Low
81.10
Previous Close
81.18
Daily Price Gain
0.02
YTD High
81.50
YTD High Date
Nov 1, 2017
YTD Low
26.60
YTD Low Date
Jan 3, 2017
YTD Price Change
54.04
YTD Gain
198.97%
52 Week High
81.50
52 Week High Date
Nov 1, 2017
52 Week Low
23.50
52 Week Low Date
Dec 22, 2016
52 Week Price Change
46.17
52 Week Gain
131.77%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 27. 2016
26.29
Mar 2. 2017
36.52
44 Trading Days
38.92%
Link
LONG
Sep 26. 2017
58.30
Oct 26. 2017
70.40
22 Trading Days
20.75%
Link
Company Information
Stock Symbol
AAAP
Exchange
NasdaqGS
Company URL
http://www.adacap.com
Company Phone
-
CEO
Stefano Buono
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
-
About

Advanced Accelerator Applications SA is a radiopharmaceutical company, which develops, produces and commercializes molecular nuclear medicine products. It offers research and development in medicinal and pharmaceutical therapeutic products mainly focusing in cardiology and neurology. The company manufactures both diagnostic and therapeutic MNM products for commercialization. Advanced Accelerator Applications was founded in 2002 by Stefano Buono and is headquartered in Saint Genis Pouilly, France.

Description

Advanced Accelerator Applications SA is a radiopharmaceutical company that develops, produces and sells molecular nuclear medicine (MNM), diagnostic and therapeutic products. The Company's lead therapeutic candidate, Lutathera, is being developed for the treatment of midgut neuroendocrine tumors (NETs). The Company has a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The Company's commercial products include Gluscan /Gluscan 500/Barnascan, IASOflu, IASOdopa, IASOcholine, MIBITEC/Adamibi and Leukokit. Lutathera is a solution of a Lu-177-labeled analogue of somatostatin, a hormone that acts as a regulator of the endocrine system. Somakit is the Company's companion PET diagnostic product candidate for Lutathera. Annexin V-128 is a SPECT diagnostic candidate for the assessment of apoptotic and necrotic processes.